Sublingual Misoprostol 600µg Aims for Non-Inferiority to Oxytocin in Preventing Post-Partum Hemorrhage

Globally, post-partum hemorrhage (PPH) remains a leading cause of maternal mortality, particularly in low-resource settings like Uganda. The current gold standard for PPH prevention is oxytocin, administered intravenously or intramuscularly. However, oxytocin requires cold chain storage and skilled administration, posing significant logistical challenges in remote areas. This often limits its availability and effectiveness. Misoprostol, a synthetic prostaglandin E1 analog, offers a promising alternative due to its oral/sublingual administration, heat stability, and lower cost, addressing critical gaps in access and infrastructure for PPH prevention.

This randomized, triple-blinded, non-inferiority trial, conducted in Uganda, aimed to compare sublingual misoprostol 600µg against 10 IU oxytocin for the active management of the third stage of labor to prevent post-partum hemorrhage (PPH). The study enrolled 1786 participants. The primary endpoint was the incidence of PPH, with non-inferiority defined as misoprostol being no more than 6% worse than oxytocin. The control arm received 10 IU oxytocin. The trial design sought to determine if misoprostol could provide comparable efficacy to oxytocin under real-world conditions.

The core objective of this randomized controlled trial was to assess the non-inferiority of sublingual misoprostol 600µg compared to 10 IU oxytocin in the active management of the third stage of labor, specifically for the prevention of post-partum hemorrhage (PPH). The alternative hypothesis posited that sublingual misoprostol 600µg would be non-inferior to 10 IU oxytocin, with a predefined non-inferiority margin set at 6%. This means the study aimed to show that misoprostol's efficacy would not be more than 6% worse than oxytocin's. Conversely, the null hypothesis stated that 10 IU oxytocin would be superior to sublingual misoprostol 600µg. The trial's design was set to determine if misoprostol, a more accessible and heat-stable option, could offer comparable protection against PPH. While the abstract clearly defines these hypotheses and the non-inferiority margin, it does not present the actual outcomes, such as the incidence of PPH in each arm, mean blood loss, or the calculated difference between the interventions. Therefore, the specific numerical results demonstrating whether misoprostol met the non-inferiority criteria against oxytocin are not available in this abstract.